BETHESDA, Md., June 8 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that Christian Itin, Ph.D., Micromet’s President and Chief Executive Officer, will present a corporate overview at three upcoming investor conferences:
Jefferies 2010 Global Life Sciences Conference | |
Wednesday, June 9, at 2 PM ET | |
Grand Hyatt, New York City | |
9th Annual Needham Healthcare Conference | |
Thursday, June 10 at 8:40 AM ET | |
New York Palace Hotel, New York City | |
31st Annual Goldman Sachs Global Healthcare Conference | |
Wednesday, June 16 at 11 AM ET | |
Century Plaza Hyatt Regency, Los Angeles | |
The presentations will be webcast live and may be accessed by visiting the Micromet website at www.micromet-inc.com. A replay of the webcasts will also be available on the Company’s website.
About Micromet, Inc.
Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. Two of Micromet’s BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including sanofi-aventis, Bayer Schering Pharma, Merck Serono, Boehringer Ingelheim, MedImmune and Nycomed. Additional information can be found at www.micromet-inc.com.
SOURCE Micromet, Inc.
